Indian drug market ballooning

If you had any doubt why Pfizer, GlaxoSmithKline, and other Big Pharma companies are drooling over business in the developing world, take a look at a new Deutsche Bank report on the Indian drug market. Rising population and a growing middle class are expected to push drug sales up by 8 percent annually--much higher than the growth rate predicted for elsewhere in the world. By 2015, sales in the subcontinent are expected to surpass $31 billion.

- see the coverage in the Economic Times

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.